Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Preparing For Increasing Mounjaro Demand On Top Of Solid Launch

Executive Summary

The pharma is increasing its manufacturing capacity for tirzepatide, mindful of its potential in a second indication of obesity and the supply issues faced by competitor Novo Nordisk.

You may also be interested in...



Stock Watch: The Pandemic Still Permeates Through Q3 Earnings

While big tech is suffering from a return to normality after the pandemic, big pharma always had a recovery in its base business to return to. But after the third-quarter earnings season, it seems both base and pandemic pharmaceutical businesses are still co-existing for now.

Imminent Madrigal, Viking Trial Readouts Will Shape NASH R&D Expectations

While neither company reported new data from their ongoing trials at AASLD, the firm’s competing THRβ agonists are viewed as leading lights in the non-alcoholic steatohepatitis competition.

Amgen’s Olpasiran Maintains Competitive Profile In Lp(a) Class

The lipoprotein(a)-lowering antisense drug olpasiran reduced the cardiovascular disease risk factor Lp(a) by up to 101.1% relative to placebo. A Phase III trial will begin in December. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147296

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel